Navigation Links
Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication
Date:9/30/2013

NEW YORK, Sept. 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have begun a Phase I clinical research study of an investigational medication for Type 2 Diabetes Mellitus.  The study is being conducted to assess the safety and tolerability of multiple daily doses of the investigational medication over periods of up to 28 days.  

Diabetes has become one of the most prevalent diseases in the United States, with approximately 2 million people diagnosed each year.  The Center for Disease Control and Prevention estimates that roughly 35% of the population over the age of 20 is pre-diabetic.  For those over the age of 65, this number increases to 50%.  Clinilabs understands the growing need for treatment options in this field and is dedicated to helping sufferers combat the disease.  In response to the study award, Lead Recruiter Carrie Sorkin states: "Patients understand that clinical trials are a great way to find alternative treatment options for diabetes.  At Clinilabs, we have seen this first-hand through the great success we have had in our recruitment efforts."

Clinilabs is currently enrolling male and female volunteers, between the ages of 18 and 70, who have been diagnosed with Type 2 Diabetes Mellitus.  Any female patients interested in volunteering for this study must not be of childbearing potential. Patients must be on a stable treatment regimen for at least 4 weeks prior to screening and must have a body weight of above 45.0 kg.

Individuals in the Central New Jersey area who would like to participate can contact our dedicated call center at 212-994-4567 to prequalify.  Additional information may also be found by visiting www.clinilabs.com/volunteers.  If you are a Physician in the New Jersey or New York area and are interested in referring patients for this trial please contact us at info@clinilabs.com.

About Clinilabs Inc.

Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations.  The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide.  Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, metabolic, and Japanese bridging are among our strengths.  Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CROs for specialty projects.  For more information, please visit www.clinilabs.com.

Media Contact: Hannah DAoust, Clinilabs, 646-215-6480, hdaoust@clinilabs.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Clinilabs
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Leading evolutionary scientist to discuss how genome of bacteria has evolved
2. Worlds leading coral experts to gather in Australia
3. Putting plants online: 4 leading botanical gardens to create first online catalog of all plants
4. EMBO welcomes 55 leading life scientists as members
5. Leading statistician receives national citation award
6. Leading childhood asthma group supports federal asthma action plan to reduce disparities
7. BiOptix Participates in Leading Life Sciences Event BioWest 2012
8. Team including UC Riverside entomologist honored for research leading to healthier potato chips
9. Aware Enables Automated Delivery of Radiation Dose Information Through Integration With Leading Radiology Reporting System
10. Discovery of pathway leading to depression reveals new drug targets
11. Leading RSV researcher publishes work at Le Bonheur Childrens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... and Webster Bank, today announced first round funding to three startups through the ... early-stage financial support to new business startups affiliated with UConn. , The UConn ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The AMA ... 11 high school graduates from across the nation. The scholarships are created through funds ... member dues. , Scholarship criteria are set by the AMA Scholarship Committee, which is ...
(Date:4/21/2017)... ... ... Frederick Innovative Technology Center, Inc. (FITCI), a business incubator ... a $77,518 grant from the Rural Maryland Council (RMC) to support refurbishment of ... incubator. A non-profit corporation, FITCI is a public-private partnership of the governments of ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... their strategic partnership to offer a full spectrum of digital security goods and ... of biometric products and the ground-breaking proactive cybersecurity services and products through Assured ...
Breaking Biology Technology: